Harrow
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1998-01-01
- Employees
- 315
- Market Cap
- -
- Website
- http://www.harrow.com
- Introduction
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
Nordic Pharma Launches Authorized Generic of Maxitrol for Bacterial Eye Infections
• Nordic Pharma, a subsidiary of Nordic Group B.V., has partnered with Harrow to launch an authorized generic version of Maxitrol ophthalmic suspension for treating bacterial eye infections. • The new generic alternative enters a market where Maxitrol and its generic equivalents generated annual sales of $20.8 million in the U.S. as of January 2025, according to IQVIA data. • This product expansion strengthens Nordic Pharma's generic portfolio and aims to provide patients with a more affordable prescription option for treating ocular bacterial infections.
Eyenovia and Betaliq Plan Reverse Merger to Create Innovative Ophthalmic Technology Company
Eyenovia has entered into a non-binding letter of intent with Betaliq to create a new publicly-listed eye care company valued at approximately $92 million, with Betaliq shareholders owning 83.7% of the combined entity.
Harrow Secures Five-Year Supply Agreement for TRIESENCE® and Initiates Development of Next-Generation Version
• Harrow has executed a five-year strategic supply and development agreement with the current contract manufacturing organization for TRIESENCE®, ensuring stable supply of the ocular corticosteroid. • The company has begun developing an enhanced version of TRIESENCE®, with plans to submit a new drug application (NDA) to the FDA by the end of 2027. • TRIESENCE® is FDA-approved for visualization during vitrectomy and treatment of ocular inflammatory conditions unresponsive to topical corticosteroids, addressing a product previously on the FDA's Drug Shortage List.